ONWARD
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014).
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH-AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces it has completed enrollment in the Up-LIFT study, a pivotal trial to evaluate the safety and effectiveness of ARC Therapy to restore hand and arm function in people with spinal cord injury (SCI). Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology.
ONWARD has now reached the study’s enrollment ceiling of 65 subjects, enrolled at 14 leading SCI research sites throughout the United States, Canada, the United Kingdom, and the Netherlands. The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) to treat upper extremity functional deficits in people with chronic tetraplegia.
“The study reached its enrollment objective in under 12 months despite lock-downs, travel restrictions, and other COVID-related challenges,” said Dave Marver, Chief Executive Officer of ONWARD. “This milestone underscores the SCI community’s enthusiasm for this promising therapy. We will now work with determination to prepare submissions to regulatory authorities in the US and Europe so we can bring this important therapy to market for the benefit of people with SCI and their loved ones.”
“For individuals with impaired arm and hand function due to spinal cord injury, improved hand function directly translates into meaningful gains in terms of quality of life - being able to eat, dress or perform other daily life activities,” said Edelle Field-Fote , PT, PhD, FAPTA, FASIA, co-PI of the Up-LIFT trial and Director of Spinal Cord Injury Research at Shepherd Center and Professor of Rehabilitation Medicine at Emory University School of Medicine. “It was very rewarding to take part in this important trial and collaborate with many of the most highly respected SCI rehabilitation centers across the globe.”
“The end of enrollment for this trial marks a significant milestone in bringing non-invasive stimulation for restoring hand and arm function to people living with spinal cord injury” said Chet Moritz , PhD, co-PI of the Up-LIFT trial and Associate Professor in the Departments of Electrical & Computer Engineering and Rehabilitation Medicine at the University of Washington in Seattle. “We are hopeful this study can lead to the broad availability of this important therapy.”
The company expects to initially commercialize ARC Therapy in the US, Germany, France, UK, Switzerland, and the Netherlands. To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com .
About ONWARD
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM ) or external (ARCEX ) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX . The company’s first FDA pivotal trial, called Up-LIFT, commenced in January 2021 and has now completed enrollment with 65 subjects worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com .
About Dr. Edelle Field-Fote
Dr. Edelle Field-Fote has a 20+ years of SCI research, building on her clinical background as a physical therapist and Ph.D. training in an animal model of SCI. Her contributions to SCI literature include the largest study to date of locomotor training for persons with chronic, motor-incomplete SCI, as well as the first-ever study of a rehabilitation intervention to promote neuroplasticity for improved hand function in persons with tetraplegia. Dr. Field-Fote’s research has been funded by the National Institutes of Health (NIH) since 1997, and also by the National Institute on Independent Living, Disability and Rehabilitation Research (NILDRR) and the Department of Defense (DoD). Dr. Field-Fote is the editor/author of the textbook Spinal Cord Injury Rehabilitation (FA Davis Publishers).
About Dr. Chet Moritz
Dr. Chet Moritz is Associate Professor in the departments of Electrical & Computer Engineering, Rehabilitation Medicine, and Physiology & Biophysics at University of Washington, Seatlle. He was named an Allen Distinguished Investigator and appointed to the Christopher & Dana Reeve International Consortium on Spinal Cord Repair. Chet serves as the Co-Director for the Center for Neurotechnology, an NSF Engineering Research Center (ERC). Chet directs the Restorative Technologies Laboratory (RTL) which focuses on developing technologies to treat paralysis due to spinal cord injury. Current research in the lab includes a multi-site clinical trial of spinal stimulation to restore hand function for people with spinal cord injury, stimulation to improve walking for children with cerebral palsy, and optogenetic stimulation to guide neuroplasticity and recovery in the injured spinal cord of animals.
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
50116485 M 33513785 / 1
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005922/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elite Athletes Join Forces With Global Leaders to Launch Adapt2Win, a Bold Climate Adaptation Campaign Ahead of COP3027.10.2025 13:30:00 CET | Press release
Top Athletes Raheem Sterling, Misty Copeland, Maya Gabeira, DeAndre Jordan, Stamp Fairtex, Ferdinand Omanyala, and Others Join New Global Campaign Today marks the global launch of Adapt2Win, a powerful new campaign calling on world leaders to prioritize and fund climate adaptation. Backed by elite athletes from across the globe—including NBA player DeAndre Jordan, Brazilian big wave surfer Maya Gabeira, acclaimed ballerina Misty Copeland, professional footballer Raheem Sterling, Thai mixed martial artist Stamp Fairtex, Kenyan sprinter Ferdinand Omanyala, and more—the initiative demands urgent investment in innovative solutions that protect people, communities, and ecosystems from the accelerating impacts of climate change today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027062179/en/ Credit Adapt2Win.org Adapt2Win is supported by partners including the Gates Foundation, Wellcome, Ban Ki-moon Centre, Global Citizen, G
Tecnotree Recognized as a Major Player by IDC MarketScape 202527.10.2025 13:26:00 CET | Press release
Tecnotree has been recognized as a Major Player in the IDC MarketScape: Worldwide Customer Experience Platforms for Telecommunications 2025 (Doc # US52580525, August 2025). We believe this acknowledgment underscores Tecnotree’s commitment to delivering innovative and flexible customer experience solutions for the telecommunications industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027811702/en/ Tecnotree Recognized as a Major Player by IDC MarketScape 2025! The IDC MarketScape evaluates vendors based on their capabilities and strategies in customer experience (CX) platforms for telecom operators worldwide. Tecnotree’s modular BSS platform provides a comprehensive suite of CX solutions including unified catalog, customer value management (CVM), voice of the customer, loyalty manager, order and subscription management, customer self-service portals, and billing and charging. At the same time, its AI-driven Sensa plat
H2SITE Strengthens Its Leadership With a New Control Room, Developed in Collaboration With Siemens, to Remotely Monitor Membrane Reactor and Separator Technologies for Hydrogen Production Across Europe27.10.2025 12:01:00 CET | Press release
H2SITE, the deep-tech start-up revolutionizing high-purity hydrogen production through cutting-edge palladium membrane technology, is scaling up its industrial presence with projects deployed across several European countries. To ensure performance and continuous optimization of its membrane reactors and separators, H2SITE has launched a control and data collection room built in collaboration with Siemens, based on the beta version of Siemens WinCC Unified Collaboration and Datahub software. The control room is already integrated and will be further developed across various ongoing and future projects, covering a wide range of market segments that reflect the versatility of H2SITE’s membrane-based technology. In the field of ammonia (NH₃) cracking, projects such as EIC, APOLO, and KATA are integrating this tool to monitor hydrogen production efficiency and system reliability in real time. Within the Waste-to-Hydrogen (WtH₂) segment, the HYIELD project is applying the control room to op
Comply Acquires Trailight to Accelerate Global Expansion and Create the Industry’s First Fully Integrated Firm and Employee Compliance Platform27.10.2025 10:07:00 CET | Press release
Comply, the leading provider of regulatory and compliance technology solutions for financial firms, today announced it has acquired Trailight, the U.K.’s leading provider of purpose-built solutions for managing conduct risk, competence frameworks, and global accountability regimes. With the addition of Trailight, Comply becomes the first and only unified compliance platform to bring together firm compliance, employee compliance, individual accountability regime and archiving solutions across jurisdictions. The acquisition strengthens Comply’s growing presence in Europe, where demand for modern, integrated compliance solutions continues to accelerate amid expanding regulatory frameworks and accountability mandates. “Over the past year, we’ve seen remarkable growth across Europe as firms seek to consolidate their compliance technology and gain greater transparency into both firm and employee obligations,” said Michael Stanton, CEO of Comply. “Trailight is the perfect complement to that s
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 07:39:00 CET | Press release
Vinmec Health System attracts international patients to Vietnam for treatment Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom